Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes

Company Anticipates Six Month Review and Potential Launch in Early 2025 "We are confident in the benefit/risk profile of sotagliflozin for people with type 1 diabetes and CKD, and our team has been resolute in identifying and pursuing a regulatory path forward," said Lonnel Coats, director and chief executive officer. "We are now one step closer to bringing this important potential therapy to market for the many people who suffer from type 1 diabetes and CKD, and who could benefit from an adjunct to insulin ...